Where can I listen to this podcast?

This podcast is available on 10 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.

Does this podcast accept guests?

Yes, this podcast regularly features guests.

PulmPEEPs

Claim This Podcast

by PulmPEEPs

4.9(84 reviews)

120 episodes

Updated Daily

Accepts GuestsHas SponsorsLocation 🇺🇸

Podcast Authority

Beta

GoodBased on show quality, social media presence, reviews, charts, and more

Quality99

Social0

YouTube0

Engagement90

Learn more

Podcast Overview

Pulmonary and Critical Care content for learners and practitioners of all levels

Language

🇺🇲

Publishing Since

10/27/2021

Visit Website View on Apple Podcasts RSS Feed

🇺🇸 Charts #3

Outreach generated

Apple 142

Spotify 827

Instant mention tracking

Perfect fit!

Unlock The Full Podcast Authority Score Report

See how your podcast performs across key metrics

Podcast Authority

Beta

GoodBased on show quality, social media presence, reviews, charts, and more

Quality99

Social0

YouTube0

Engagement90

Learn more

Excellent Areas

Good Performance

Growth Opportunities

excellent

Episode Length

39 minutes

Performing excellently!

good

Publishing Consistency

Every 13 days

Recommendations available

Unlock the full report to see detailed tips

poor

Episode Thumbnails

Recommendations available

Unlock the full report to see detailed tips

+16 More Metrics

Unlock comprehensive insights including:

• YouTube presence analysis
• Social media reach metrics
• RSS compliance scoring
• Podcast 2.0 features
• Technical standards

What's Included in Your Full Report

Detailed Analytics

Complete breakdown of all 19 authority metrics
Personalized recommendations for each metric
Industry benchmarks and comparisons
Technical RSS feed analysis and compliance scoring

Growth Strategies

Step-by-step action plans for improvement
Quick wins to boost your score immediately
Pro tips from successful podcasters

Get your free podcast insights report

See how your show performs across every key metric

Instant delivery

No spam

Attract Better Guests

High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.

Secure Sponsorships

Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.

Grow Your Audience

Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.

3 verified contact emails on file for PulmPEEPs

Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.

See contact details

Recent Episodes

$Episode thumbnail for 120. Pulm PEEPs & Irish Thoracic Society: Understanding Refractory Chronic Cough$

April 7, 2026

120. Pulm PEEPs & Irish Thoracic Society: Understanding Refractory Chronic Cough

We’re excited today to launch our first episode in collaboration with the <a href="https://irishthoracicsociety.com/">Irish Thoracic Society </a>and their <a href="https://irishthoracicsociety.com/education/podcast/">podcast series</a>. The Irish Thoracic Society represents respiratory professionals throughout Ireland and is dedicated to championing excellence in the prevention, diagnosis, and clinical care of respiratory disease through its work in advocacy, education and research. In today’s episode, we explore the complex and often overlooked world of refractory chronic cough — a condition that can significantly impact patients’ quality of life but is frequently misunderstood or underdiagnosed. With insights from leading respiratory specialists in Ireland and the United States, we discuss the latest thinking on diagnosis, management, and emerging treatments aimed at improving outcomes for patients and helping clinicians navigate this challenging area of respiratory medicine. Joining us are renowned experts Professor Lorcan McGarvey and Professor Brendan Canning, both internationally recognised leaders in respiratory medicine and cough research. Together, they share their perspectives on the neurobiology of chronic cough, the considerable morbidity experienced by patients, and how clinicians can approach diagnostic investigations more effectively. We also explore current treatment strategies and promising new therapies on the horizon as chronic cough increasingly gains recognition as a disease in its own right — rather than simply a symptom. Whether you’re a clinician, researcher, or simply interested in advances in respiratory medicine, this episode offers valuable insights into a condition that is finally receiving the attention it deserves. Meet Our Co-Hosts Marissa O’Callaghan is an Irish trained Respiratory fellow currently undertaking a post-doc fellow working in Erasmus MC Rotterdam in the Netherlands. She finished her Irish respiratory and Internal medicine training and Phd in 2025. Her areas of interest are interstitial and rare lung diseases. She enjoys clinical research, Med Ed, and dreaming up new medical innovations. Together with cohost Sandra Green, she founded the ITS podcast series in June 2024. Marissa O’Callaghan –<a href="https://www.linkedin.com/in/marissaocallaghan" target="_blank" rel="noreferrer noopener">LinkedIn</a> Sandra Green is an Irish-trained respiratory fellow with a strong track record in climate advocacy and multidisciplinary sustainable initiatives, as co-founder of Irish Doctors for the Environment. She has an MSc in Leadership and Innovation in Healthcare at the Royal College of Surgeons Ireland (2023–2025). With Marisssa, she co-founded the Irish Thoracic Society Podcast Productions, launching the platform in 2024 to share knowledge, insights, and innovations in respiratory care. Sandra Green – <a href="https://www.linkedin.com/in/sandragreen" target="_blank" rel="noreferrer noopener">LinkedIn</a> Meet Our Guests Lorcan McGarvey is a professor of respiratory medicine at the University of Belfast, with a focus on the neurobiology of cough. His research has significantly contributed to the understanding of cough hypersensitivity syndrome and the development of new therapeutic strategies. Lorcan is a respected voice in the field, known for his collaborative work and dedication to advancing respiratory health. Brendan Canning is a distinguished researcher at Johns Hopkins University, specializing in the mechanisms of cough and airway diseases. His pioneering studies on neural pathways and receptor targets have paved the way for novel treatments in refractory chronic cough. Brendan’s expertise and innovative approach make him a key figure in the ongoing efforts to redefine chronic cough management. In This Episode The definitions and classifications of chronic cough, including unexplained, refractory, and unexplained refractory cough The importance of a thorough clinical history and focused diagnostics over exhaustive testing Common causes of chronic cough The role of personalized, multidisciplinary management—combining pharmacologic, speech therapy, and psychological support—to improve quality of life for even the most challenging patients. The concept of cough hypersensitivity syndrome and its role in refractory cases Evidence-based approach to treatment, including pharmacologic and non-pharmacologic options Emerging therapies on the horizon, including novel receptor modulators and neuromodulatory agents and ongoing clinical trials in this rapidly evolving field The impact of chronic cough on mental health, social life, and overall quality of life The importance of reframing chronic cough as a disease entity in its own right References and Further Reading Chung KF, Pavord ID. Prevalence, pathogenesis, and causes of chronic cough. Lancet. 2008;371(9621):1364-1374. Gibson PG, Vertigan AE. Management of chronic refractory cough. BMJ. 2015;351:h5590. Matsumoto H, Kanemitsu Y, Ohe M, Tanaka H, Terada K, Nishi K, et al. Real-world usage and response to gefapixant in refractory chronic cough. ERJ Open Res. 2025;11(4):01037-2024. doi:10.1183/23120541.01037-2024. McGarvey LP, Birring SS. Cough hypersensitivity syndrome: a novel paradigm for understanding cough. Lancet Respir Med. 2014;2(8):647-656. Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Ribas CD, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136. Parker SM, Smith JA, Birring SS, Chamberlain-Mitchell S, Gruffydd-Jones K, Haines J, et al. British Thoracic Society clinical statement on chronic cough in adults. Thorax. 2023;78(Suppl 1):S3-S19. Smith JA, Woodcock A. Chronic cough. N Engl J Med. 2006;354(2):136-144. Song WJ, Dupont L, Birring SS, Chung KF, Dąbrowska M, Dicpinigaitis P, et al. Consensus goals and standards for specialist cough clinics: the NEUROCOUGH international Delphi study. ERJ Open Res. 2023;9(6):00618-2023. doi:10.1183/23120541.00618-2023. Song WJ, McGarvey L, Cho PSP, Mazzone SB, Chung KF, editors. Chronic cough. Sheffield: European Respiratory Society; 2025.

March 24, 2026

119. Guideline Series: Pulmonary Embolism

We are unbelievably excited this week to be reviewing the hot-off-the-presses 2026 Multi-Society (AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN) Pulmonary Embolism Guidelines with lead author Dr. Mark A. Creager. We will talk about key updates in these guidelines compared to prior practice, including the new risk classification model, and provide an overview from diagnosis to follow-up. Given the clinical importance and prevalence of pulmonary embolism, these guidelines are certainly going to shape practice going forward, so this episode is a can’t miss! Watch the full video of this episode with graphics and helpful teaching visuals on our YouTube channel: <a href="https://www.youtube.com/@pulmpeeps">https://www.youtube.com/@pulmpeeps</a> <figure class="wp-block-image size-full"><img fetchpriority="high" decoding="async" width="819" height="1024" src="https://www.pulmpeeps.com/wp-content/uploads/2026/03/PE-Face-Sheet-Small.png" alt="" class="wp-image-2336" srcset="https://pulmpeeps.blubrry.net/wp-content/uploads/2026/03/PE-Face-Sheet-Small.png 819w, https://pulmpeeps.blubrry.net/wp-content/uploads/2026/03/PE-Face-Sheet-Small-240x300.png 240w, https://pulmpeeps.blubrry.net/wp-content/uploads/2026/03/PE-Face-Sheet-Small-768x960.png 768w" sizes="(max-width: 819px) 100vw, 819px" /></figure> Meet Our Guest Dr. Mark Creager is a Professor of Medicine at Dartmouth Hitchcock Medical Center where he specializes in Cardiovascular Medicine with an emphasis on venous thromboembolic disease. He served as the lead author of the 2026 Pulmonary Embolism Guidelines. Article and Reference <a href="https://www.jacc.org/doi/10.1016/j.jacc.2025.11.005?gad_source=1&gad_campaignid=23587533967&gbraid=0AAAABAJl-Mpqjn_iBkvLHfvftG2esTpXA&gclid=CjwKCAjwyYPOBhBxEiwAgpT8PxR6AjUhniUq4VYqsBaU6-qT4lUSMsVpE5LQodIHdJH_LrYTngM4-BoCCcgQAvD_BwE">Creager MA, Barnes GD, Giri J, Mukherjee D, Jones WS, Burnett AE, Carman T, Casanegra AI, Castellucci LA, Clark SM, Cushman M, de Wit K, Eaves JM, Fang MC, Goldberg JB, Henkin S, Johnston-Cox H, Kadavath S, Kadian-Dodov D, Keeling WB, Klein AJP, Li J, McDaniel MC, Moores LK, Piazza G, Prenger KS, Pugliese SC, Ranade M, Rosovsky RP, Russo F, Secemsky EA, Sista AK, Tefera L, Weinberg I, Westafer LM, Young MN. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026 Feb 19:S0735-1097(25)10161-7. doi: 10.1016/j.jacc.2025.11.005. Epub ahead of print. PMID: 41712898.</a> Key Learning Points Why these guidelines matter: This is the first joint AHA/ACC clinical practice guideline specifically on acute PE, bringing together a truly multidisciplinary writing committee (cardiology, pulmonology, hematology, emergency medicine, interventional radiology, surgery, and others). Prior guidelines existed from individual societies, but nothing this comprehensive had been updated in roughly five to six years. New PE clinical categories (A through E): One of the most impactful changes is replacing the old “massive/submassive” and “low/intermediate/high risk” labels with five categories that form a severity continuum. Category A is subclinical (incidental PE found on imaging in asymptomatic patients). Category B covers symptomatic but low-severity patients. Category C is where much of the clinical complexity lives — symptomatic, hemodynamically stable patients subdivided into C1, C2, and C3 based on RV function and biomarkers. Category D represents incipient cardiopulmonary failure (transient hypotension, normotensive shock with end-organ dysfunction). Category E is frank cardiopulmonary failure, with E2 being the sickest — refractory or recurrent cardiac arrest. Respiratory modifiers (hypoxia requiring supplemental oxygen) layer onto C, D, and E. Diagnostic approach: Clinical evaluation comes first — history, exam, and validated decision tools (Wells score, revised Geneva, PERC). If clinical probability is low and D-dimer is normal, imaging can be safely avoided. If either is concerning, imaging is warranted. CTPA remains the preferred imaging modality due to superior sensitivity, specificity, wide availability, and ability to assess clot burden and alternative diagnoses. VQ scanning is still appropriate when CTPA is contraindicated, and VQ SPECT offers better reproducibility and specificity than traditional planar VQ if available. Echocardiography is not a diagnostic test for PE but is important for risk stratification — RV size, TAPSE, and tissue Doppler measures all contribute prognostic information. Anticoagulation updates: Anticoagulation remains the cornerstone of treatment. For patients potentially needing advanced therapies (C3, D, E), parenteral anticoagulation is started first. A notable recommendation: low molecular weight heparin is generally preferred over unfractionated heparin, based on evidence showing more effective VTE risk reduction, more predictable pharmacokinetics, no need for routine monitoring, lower rates of heparin-induced thrombocytopenia, and no increase in major bleeding. The committee acknowledged this may create discomfort for clinicians accustomed to unfractionated heparin’s easy reversibility, but the difficulty of achieving and maintaining therapeutic levels with UFH was a significant concern. Advanced therapies: Catheter-based thrombolysis, mechanical thrombectomy, systemic thrombolysis, and surgical embolectomy all received mostly class 2B recommendations (“can consider”) for C3 and D categories, reflecting that current evidence shows improvement in short-term surrogate measures (RV/LV ratio, hemodynamics) but lacks definitive hard outcome data on mortality. For category E1 patients, recommendations are stronger (class 2A). Multiple trials are expected soon — HI-PEITHO, PEERLESS-2, PE-TRACT, PERSEVERE, TORPEDO, and PROG — that should substantially inform future updates. PERT teams: Pulmonary embolism response teams are encouraged, particularly for C3, D, and E patients. They’ve been shown to reduce length of stay. For institutions without PERT capability, establishing consultation networks with larger centers is recommended. Post-PE follow-up: Patients shouldn’t be “left in the wilderness” after discharge. The guidelines recommend communication within the first week to ensure understanding of diagnosis and treatment, an in-person visit at or before three months to assess for persistent symptoms and discuss anticoagulation duration, ongoing surveillance for chronic thromboembolic pulmonary disease, and periodic reassessment for those on extended anticoagulation. Infographics <figure class="wp-block-image size-large"><img decoding="async" width="1024" height="606" src="https://www.pulmpeeps.com/wp-content/uploads/2026/03/Pulm-PEEPs-PE-infographic-Image-Small-1024x606.png" alt="" class="wp-image-2334" srcset="https://pulmpeeps.blubrry.net/wp-content/uploads/2026/03/Pulm-PEEPs-PE-infographic-Image-Small-1024x606.png 1024w, https://pulmpeeps.blubrry.net/wp-content/uploads/2026/03/Pulm-PEEPs-PE-infographic-Image-Small-300x178.png 300w, https://pulmpeeps.blubrry.net/wp-content/uploads/2026/03/Pulm-PEEPs-PE-infographic-Image-Small-768x455.png 768w, https://pulmpeeps.blubrry.net/wp-content/uploads/2026/03/Pulm-PEEPs-PE-infographic-Image-Small-500x296.png 500w, https://pulmpeeps.blubrry.net/wp-content/uploads/2026/03/Pulm-PEEPs-PE-infographic-Image-Small.png 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

February 24, 2026

118. Pulm PEEPs Pearls: Spontaneous Breathing Trials

Furf and Monty are back with another Pulm PEEPs Pearls episode. The topic of today’s discussion is an often discussed, but often misunderstood, test; the methacholine challenge. They’ll review when to utilize this test, how it should be performed, and the appropriate interpretation. Contributors This episode was prepared with research by Pulm PEEPs Associate Editor George Doumat. Dustin Latimer, another Pulm PEEPs Associate Editor, assisted with audio and video editing. Key Learning Points What the Test Measures <ul class="wp-block-list"> <li>Methacholine challenge is a direct bronchial provocation test of airway hyperresponsiveness (AHR), a core physiologic feature of asthma.</li> <li>Anyone will bronchoconstrict at high enough concentrations — the test looks for an abnormal threshold.</li> <li>The key endpoint is the PC20: the methacholine concentration causing a 20% fall in FEV1. <ul class="wp-block-list"> <li>Abnormal in adults: PC20 ≤ 8–16 mg/mL</li> </ul> </li> </ul> Test Performance <ul class="wp-block-list"> <li>Meta-analyses: pooled sensitivity ~60%, specificity ~90%.</li> <li>Real-world cohorts: sensitivity 55–62%, specificity 56–100% (varies by population, protocol, and threshold used).</li> <li>Not a standalone yes/no test — best used as part of a broader diagnostic pathway.</li> </ul> Where It Fits in the Asthma Workup The test belongs in a stepwise approach: <ol start="1" class="wp-block-list"> <li>Step 1: Spirometry + bronchodilator response</li> <li>Step 2: Add FeNO and/or peak flow variability (if available)</li> <li>Step 3: If the picture is still unclear → methacholine challenge</li> </ol> It is most useful for symptomatic patients with normal spirometry and no bronchodilator reversibility. Given its cost, mild risk, and discomfort, it should not be a first-line test — most asthma diagnoses do not require it. Technique and Medication Prep Technique <ul class="wp-block-list"> <li>ERS guidelines favor tidal breathing over deep inspiratory maneuvers.</li> <li>Deep breaths can be bronchoprotective and blunt the response, reducing sensitivity — especially in mild or well-controlled asthma.</li> </ul> Medication Washout (to Avoid False Negatives) <figure class="wp-block-table"><table class="has-fixed-layout"><thead><tr><td>Medication Class</td><td>Washout Period</td></tr></thead><tbody><tr><td>Short-acting beta-agonists (SABA)</td><td>≥ 6 hours</td></tr><tr><td>Long-acting beta-agonists (LABA)</td><td>~24 hours</td></tr><tr><td>Ultra-long-acting beta-agonists</td><td>~48 hours</td></tr><tr><td>Short-acting anticholinergics (e.g., ipratropium)</td><td>~12 hours</td></tr><tr><td>Long-acting muscarinic antagonists (LAMA, e.g., tiotropium)</td><td>7 days</td></tr></tbody></table></figure> <ul class="wp-block-list"> <li>Inhaled corticosteroids, leukotriene blockers, and antihistamines do not significantly affect the test acutely — continue these. Withdrawing ICS also carries its own risk for asthma patients.</li> <li>Practical tip: Spell out exactly what to hold and when — for both the patient and the PFT lab — at the time the test is ordered.</li> </ul> Interpreting Results Negative Test (PC20 > 16 mg/mL) <ul class="wp-block-list"> <li>Very high negative predictive value in symptomatic adults.</li> <li>Makes current asthma quite unlikely (assuming proper test conduct).</li> <li>This is the test’s greatest strength: it is an excellent rule-out test.</li> </ul> Positive Test (PC20 ≤ 8–16 mg/mL) <ul class="wp-block-list"> <li>More nuanced — airway hyperresponsiveness is not unique to asthma.</li> <li>Can be positive in: chronic cough, allergic rhinitis, COPD, and even some healthy asymptomatic individuals.</li> <li>A positive result raises probability but must be interpreted alongside the clinical story, variable respiratory symptoms, peak flow variability, FeNO, and ICS response.</li> </ul> Safety and Risks <ul class="wp-block-list"> <li>Overall, the test is quite safe; significant adverse effects are rare.</li> <li>Temporary breathing discomfort is expected (bronchoconstriction is being induced).</li> <li>Severe bronchospasm is possible: <ul class="wp-block-list"> <li>A trained clinician should be available; SABA inhaler/nebulizer must be immediately on hand; a physician should be reachable in the facility.</li> </ul> </li> <li>Contraindications / cautions: <ul class="wp-block-list"> <li>Avoid if FEV1 < 70% predicted or < 1–1.5 L (baseline obstruction greatly increases risk).</li> <li>Avoid within 3 months of an acute cardiac event (rare risk of cardiac events with unstable cardiac disease).</li> </ul> </li> </ul> Five Pearls — Quick Recap <ol start="1" class="wp-block-list"> <li>What it tests: Methacholine challenge is a direct test of AHR with high specificity but variable sensitivity — it belongs inside a diagnostic pathway, not as a standalone asthma test.</li> <li>When to use it: Most useful for symptomatic patients with normal spirometry and no bronchodilator response, after FeNO and peak flow variability have been considered.</li> <li>Technique and meds matter: Use tidal breathing protocol; respect washout intervals — especially the 7-day LAMA washout and 24–48 hour LABA window — to avoid false negatives.</li> <li>Safety: Generally safe, but can induce significant bronchoconstriction. Have a SABA available and avoid the test in patients with FEV1 < 70% predicted.</li> <li>Interpretation: A negative test (PC20 > 16 mg/mL) strongly argues against current asthma. A positive test raises probability but is not specific — interpret alongside the full clinical picture.</li> </ol> References and Further Reading <ol class="wp-block-list"> <li>Coates AL, Wanger J, Cockcroft DW, Culver BH; Bronchoprovocation Testing Task Force: Kai-Håkon Carlsen; Diamant Z, Gauvreau G, Hall GL, Hallstrand TS, Horvath I, de Jongh FHC, Joos G, Kaminsky DA, Laube BL, Leuppi JD, Sterk PJ. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017 May 1;49(5):1601526. doi: 10.1183/13993003.01526-2016. PMID: 28461290.</li> <li>Lee, J., & Song, J. U. (2021). Diagnostic comparison of methacholine and mannitol bronchial challenge tests for identifying bronchial hyperresponsiveness in asthma: a systematic review and meta-analysis. Journal of Asthma, 58(7), 883–891. <a href="https://doi.org/10.1080/02770903.2020.1739704">https://doi.org/10.1080/02770903.2020.1739704</a></li> <li>Davis BE, Blais CM, Cockcroft DW. Methacholine challenge testing: comparative pharmacology. J Asthma Allergy. 2018 May 14;11:89-99. doi: 10.2147/JAA.S160607. PMID: 29785128; PMCID: PMC5957064.</li> </ol>

120 total episodes available with 52 transcripts

Recent guests on PulmPEEPs

Guests from recent episodes — sign up to see every guest that has ever appeared on this show.

George Doumat

Guest

George Doumat MD

Guest

Doreen Addrizzo-Harris

Guest

Dr Meredith McCormack

Guest

Dr Vishwajit Hegde

Guest

Dr Sahil Pandya

Guest

Kristina Montemayor MD

Guest

Jim Devanney

Guest

Kalaila Pais

Guest

JOHN POPOVICH

Guest

MATT FREEDMAN

Guest

TIM SCIALLA

Guest

See every guest on PulmPEEPs

Similar Podcasts

Discover related shows you might enjoy

Critical Care Time

Critical Care Time Podcast

Core IM | Internal Medicine Podcast

Core IM Team

Critical Care Scenarios

Brandon Oto, PA-C, FCCM and Bryan Boling, DNP, ACNP, FCCM

Cardionerds: A Cardiology Podcast

CardioNerds

The Curbsiders Internal Medicine Podcast

EMCrit FOAM Feed

Scott D. Weingart, MD FCCM

JAMA Clinical Reviews

JAMA Network

The Clinical Problem Solvers

ICU Ed and Todd-Cast

Eddie and Todd

Emergency Medicine Cases

Dr. Anton Helman

Breathe Easy

American Thoracic Society

Emergency Medical Minute

Anesthesia and Critical Care Reviews and Commentary (ACCRAC) Podcast

Jed Wolpaw

Out of the Blue: An AJRCCM Podcast

American Thoracic Society

Harrison's PodClass: Internal Medicine Cases and Board Prep

AccessMedicine

Deep-dive analytics for PulmPEEPs

Frequently asked questions

Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.

What is PulmPEEPs?: Pulmonary and Critical Care content for learners and practitioners of all levels
How often does this podcast release new episodes?: This podcast updates daily.
Where can I listen to this podcast?: This podcast is available on 10 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
Does this podcast accept guests?: Yes, this podcast regularly features guests.

Legal Disclaimer

Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.

All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.

We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.

While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.

By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.